Press Releases

Nov 13, 2024

Lexeo Therapeutics Provides Update on Cardiac Portfolio and Reports Third Quarter 2024 Financial Results

Oct 30, 2024

Lexeo Therapeutics Announces Positive Interim Data for LX1001, First-Ever Gene Therapy to Impact the Underlying Genetic Cause of APOE4-Associated Alzheimer’s Disease, at the Clinical Trials on Alzheimer’s Disease (CTAD) Conference

Oct 22, 2024

Lexeo Therapeutics to Present New Interim Data from Phase 1/2 Trial of LX1001 at the Clinical Trials on Alzheimer’s Disease (CTAD) 2024 Conference

Sep 05, 2024

Lexeo Therapeutics to Participate in Upcoming Investor Conferences

Aug 12, 2024

Lexeo Therapeutics Reports Second Quarter 2024 Financial Results and Operational Highlights

Jul 15, 2024

Lexeo Therapeutics Announces Positive Interim Phase 1/2 Clinical Data of LX2006 for the Treatment of Friedreich Ataxia Cardiomyopathy

Jul 11, 2024

Lexeo Therapeutics Announces Investor Webcast to Report Interim Phase 1/2 Clinical Data of LX2006 for the Treatment of Friedreich Ataxia Cardiomyopathy on Monday, July 15, 2024

Jul 08, 2024

Lexeo Therapeutics Appoints Tim Van Hauwermeiren to its Board of Directors

May 09, 2024

Lexeo Therapeutics Reports First Quarter 2024 Financial Results and Operational Highlights

May 07, 2024

Lexeo Therapeutics to Participate in Upcoming Investor Conferences